Form D · Biotechnology
ViewPoint Therapeutics, Inc.
San Francisco, CA · CIK 0001673242
Offering snapshot reported Mar 15, 2018 · SEC filing
- Reported sold
- $20.9M Offering amount: $35M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 2, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 15, 2018 | Initial | $20,935,629 | No comparison | 13 | SEC filing |
| May 2, 2016 | Initial | $3,981,337 | No comparison | 17 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-307759
Includes the dollar amount for the conversion of the principal and interest of convertible promissory notes.
Source: Form D, filed Mar 15, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark Blumenkranz, M.D. | Director |
| Douglas Crawford | Director |
| Emmett T. Cunningham, Jr. | Director |
| Jason E. Gestwicki | Director |
| Ed Hurwitz | Director |
| Heath Lukatch | Director |
| Leah Makley | Director, Executive |
| Peter Moldt | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
953 Indiana Street
San Francisco, CA, 94107
San Francisco, CA, 94107